Findings on Daprodustat Dosing and Finerenone Utilization
By Ajay K. Singh, MBBS, FRCP, MBA, Charlotte Robinson - Last Updated: May 29, 2024Nephrology Times Editorial Chair Ajay K. Singh, MBBS, FRCP, MBA, co-authored two abstracts presented at the 2024 National Kidney Foundation Spring Clinical Meetings. He spoke with us to discuss a study on daprodustat (dapro) dosing among ESA-hyporesponders versus non-ESA-hyporesponders in the ASCEND program and another on the utilization of nonsteroidal MRA finerenone in adults with chronic kidney disease and type 2 diabetes.
Advertisement
Advertisement
Related Posts
Cesia Portillo discussed her poster on creating a roadmap for APOL1-mediated kidney disease (AMKD).
Suzanne Watnick shared thoughts on the Shaul G. Massry lectureship, COVID-19, kidney transplantation, and policy issues.
A. Ersin Yassa and Yasemin Balin were the winners of the inaugural Neph Madness tournament.
Martin Pollak reflected on winning the David M. Hume Memorial Award and on breakthroughs in glomerular diseases.
Sylvia Rosas shared highlights from her term as president of the National Kidney Foundation.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.